An abnormal SLUMS score should lead to a fuller clinical evaluation, not an automatic dementia diagnosis. The Saint Louis University Mental Status exam is a brief cognitive screen; next steps assess daily function, possible causes, laboratory findings, and brain structure. A low score cannot identify Alzheimer's disease or explain why someone is having difficulty. Clinicians must interpret it alongside symptoms, health history, risks, examination findings, and information from someone who knows the person well.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does an abnormal score mean?
- The next appointment focuses on real-life function
- Could something treatable be affecting the score?
- Routine tests look for causes and clues
- When are Alzheimer's biomarkers considered?
What does an abnormal score mean?
SLUMS scoring depends partly on education. For people with at least a high-school education, scores of 21–26 suggest mild impairment, while 1–20 falls within the dementia range.
Below high school, the corresponding ranges are 20–24 and 1–19, according to the Shirley Ryan AbilityLab's SLUMS reference. These labels describe screening ranges, not confirmed conditions. Education is only one consideration; symptoms, language, health problems, and the circumstances surrounding testing may also affect how a clinician interprets the result.
The next appointment focuses on real-life function
The clinician should ask what has changed, when it began, and whether cognitive problems interfere with ordinary responsibilities. Functional decline helps distinguish mild cognitive impairment from dementia, so the discussion may cover tasks such as: A family member, friend, or other care partner can provide "collateral history"—observations that supplement the patient's account. CMS includes both functional assessment and information from a knowledgeable care partner in its cognitive-assessment guidance.
- Managing medications or bills
- Preparing meals and keeping appointments
- Navigating familiar places
- Handling household or work responsibilities
- Maintaining personal care
Could something treatable be affecting the score?
A low score can have causes other than a progressive dementia. The clinician should review medications, mood, sleep, alcohol use, medical history, and neurologic findings rather than assuming Alzheimer's disease.
Possible contributors include depression, sleep apnea, delirium, medication effects, thyroid disease, vitamin deficiencies, and excess alcohol. Some are treatable, which makes this review a central part of the evaluation rather than a formality.
Routine tests look for causes and clues
The Alzheimer's Association recommends a first-line cognitive laboratory panel for most people with suspected cognitive symptoms. It includes a complete blood count, metabolic testing, thyroid-stimulating hormone, vitamin B12, homocysteine, C-reactive protein, and erythrocyte sedimentation rate. Additional tests should reflect the person's symptoms and risks.
Structural brain imaging is generally part of the workup. The Alzheimer's Association's diagnostic guideline recommends MRI, or non-contrast CT when MRI is unavailable or unsuitable. Imaging may reveal stroke, bleeding, a tumor, hydrocephalus, or patterns of brain atrophy, but it does not replace the clinical assessment.
When are Alzheimer's biomarkers considered?
If routine evaluation leaves uncertainty—or confirming Alzheimer's-related changes would affect management—a specialist may consider amyloid PET imaging or cerebrospinal-fluid biomarkers. The National Institute on Aging's biomarker guidance cautions that a positive amyloid scan supports Alzheimer's-related biology but does not, by itself, prove that Alzheimer's is causing the symptoms.
Blood-based Alzheimer's biomarkers are emerging options in specialty care for people with confirmed cognitive impairment. Availability remains limited, and the Alzheimer's Association's 2025 guideline notice says results belong within a comprehensive evaluation—not as a stand-alone dementia test. Before advanced testing, ask what question the result would answer and how it would change care.
